Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine

被引:9
|
作者
Giarola-Silva, Sarah [1 ]
Coelho-dos-Reis, Jordana G. A. [1 ]
Mourao, Marina Moraes [2 ]
Campi-Azevedo, Ana Carolina [1 ]
Nakagaki Silva, Erick E. [2 ]
Luiza-Silva, Maria [3 ]
Martins, Marina Angela [1 ]
de Oliveira Silveira-Cassette, Amanda Cardoso [1 ]
Batista, Mauricio Azevedo [1 ]
Peruhype-Magalhaes, Vanessa [1 ]
do Valle Antonelli, Lis Ribeiro [4 ]
Leite Ribeiro, Jose Geraldo [5 ]
Eloi-Santos, Silvana Maria [1 ,3 ]
Machado, Alexandre Vieira [6 ]
Teixeira-Carvalho, Andrea [1 ]
Martins-Filho, Olindo Assis [1 ]
Silva Araujo, Marcio Sobreira [1 ]
机构
[1] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Integrado Pesquisas Biomarcadores, Belo Horizonte, MG, Brazil
[2] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Helmintol & Malacol Med, Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil
[4] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Biol & Imunol Parasitaria, Belo Horizonte, MG, Brazil
[5] Secretaria Estadual Saude Minas Gerais, Belo Horizonte, MG, Brazil
[6] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Imunol Doencas Virais, Belo Horizonte, MG, Brazil
关键词
H1N1; vaccine; AS03; adjuvant; Immune response; Biomarker signature; PANDEMIC H1N1 INFLUENZA; ADVERSE EVENTS; AS03; ADJUVANT; B-LYMPHOCYTES; CHILDREN; CYTOKINE; AGE; IMMUNOGENICITY; INTERLEUKIN-10; SIGNATURES;
D O I
10.1016/j.antiviral.2017.05.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The study aimed at identifying biomarkers of immune response elicited by non-adjuvanted-(NAV) and adjuvanted-(AV) H1N1(pdm09) vaccines. The results showed that despite both vaccines elicited similar levels of anti-H1N1 antibodies at day30 after vaccination, higher reactivity was observed in AV at day180. While AV induced early changes in cell-surface molecules on monocytes, CD4(+), CDS+ T-cells and B-cells, NAV triggered minor changes, starting later on at day3. Furthermore, AV induced a late and persistent increase in TLR gene expression after day3, except for tIr4, while NAV displayed earlier but transient tlr3/4/7/9 up-regulation. Contrasting with NAV, prominent chemokine gene expression (cxcl8,cxcl9,ccl5) and a broad spectrum up-regulation of plasmatic biomarkers (CXCL8,1-6,1L-1 beta,1L-12,1-10) was evident in AV, which showed a major involvement of TNF and IL-10. Similarly, AV induced a robust IL-10-modulated proinflammatory storm, with early and persistent involvement of TNF-alpha/IL-12/IFN-gamma axis derived from NK-cells, CD4(+) and CD8(+) T-cells along with promiscuous production of IL-4/IL-5/1L-13. Conversely, NAV promotes a concise and restricted intracytoplasmic chemokine/cytokine response, essentially mediated by TNF-alpha and IL-4, with late IL-10 production by CD8(+) T-cells. Systems biology approach underscored that AV guided the formation of an imbricate network characterized by a progressive increase in the number of neighborhood connections amongst innate and adaptive immunity. In AV, the early cross-talk between innate and adaptive immunity, followed by the triad NK/CD4(+)/CD8(+) T-cells at day3, sponsored a later/robust biomarker network. These findings indicate the relevance of adjuvanted vaccination to orchestrate broad, balanced and multifactorial cellular immune events that lead ultimately to a stronger H1N1 humoral immunity. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:70 / 82
页数:13
相关论文
共 50 条
  • [11] Immune Responses in Pigs Vaccinated with Adjuvanted and Non-Adjuvanted A(H1N1)pdm/09 Influenza Vaccines Used in Human Immunization Programmes
    Lefevre, Eric A.
    Carr, B. Veronica
    Inman, Charlotte F.
    Prentice, Helen
    Brown, Ian H.
    Brookes, Sharon M.
    Garcon, Fanny
    Hill, Michelle L.
    Iqbal, Munir
    Elderfield, Ruth A.
    Barclay, Wendy S.
    Gubbins, Simon
    Bailey, Mick
    Charleston, Bryan
    PLOS ONE, 2012, 7 (03):
  • [12] Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees
    Ma Teresa Herrera
    Yolanda Gonzalez
    Esmeralda Juárez
    Fernando Hernández-Sánchez
    Claudia Carranza
    Carmen Sarabia
    Silvia Guzman-Beltran
    Ma Eugenia Manjarrez
    Marcela Muñoz-Torrico
    Lourdes Garcia-Garcia
    Eduardo Sada
    Martha Torres
    BMC Infectious Diseases, 13
  • [13] Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine
    Rouleau, Isabelle
    De Serres, Gaston
    Drolet, Jean Philippe
    Skowronski, Danuta M.
    Ouakki, Manale
    Toth, Eveline
    Landry, Monique
    Menard, Suzanne
    Gagnon, Remi
    VACCINE, 2013, 31 (50) : 5989 - 5996
  • [14] Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
    Andrews, Nick J.
    Walker, Woolf T.
    Finn, Adam
    Heath, Paul T.
    Collinson, Andrew C.
    Pollard, Andrew J.
    Snape, Matthew D.
    Faust, Saul N.
    Waight, Pauline A.
    Hoschler, Katja
    Sheasby, Liz
    Waddington, Claire
    Kerridge, Simon
    Chalk, Jeremy
    Reiner, Amanda
    John, Tessa
    Fletcher, Margaret
    Allen, Ruth
    Fineman, Natalie
    Wilkins, Su
    Casey, Michelle
    Michaelis, Louise
    Oeser, Clarissa
    Okike, Ifeanyichukwu
    Ladhani, Shamez
    Miller, Elizabeth
    VACCINE, 2011, 29 (45) : 7913 - 7919
  • [15] AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice
    Caillet, Catherine
    Piras, Fabienne
    Bernard, Marie-Clotilde
    de Montfort, Aymeric
    Boudet, Florence
    Vogel, Frederick R.
    Hoffenbach, Agnes
    Moste, Catherine
    Kusters, Inca
    VACCINE, 2010, 28 (18) : 3076 - 3079
  • [16] Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases
    Sengler, C.
    Niewerth, M.
    Kallinich, T.
    Nimtz-Talaska, A.
    Haller, M.
    Huppertz, H. -I.
    Minden, K.
    CLINICAL RHEUMATOLOGY, 2014, 33 (01) : 137 - 139
  • [17] Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
    Launay, Odile
    Duval, Xavier
    Fitoussi, Serge
    Jilg, Wolfgang
    Kerdpanich, Angkool
    Montellano, May
    Schwarz, Tino F.
    Watanveerade, Veerachai
    Wenzel, Jurgen J.
    Zalcman, Gerard
    Bambure, Vinod
    Li, Ping
    Caplanusi, Adrian
    Madan, Anuradha
    Gillard, Paul
    Vaughn, David W.
    BMC INFECTIOUS DISEASES, 2013, 13
  • [18] Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine
    Javelle, Emilie
    Soulier, Benjamin
    Brosset, Christian
    Lorcy, Solene
    Simon, Fabrice
    VACCINE, 2011, 29 (06) : 1123 - 1125
  • [19] Safety and immunogenicity of 2010-2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine Results of a randomized trial
    Scheifele, David W.
    Dionne, Marc
    Ward, Brian J.
    Cooper, Curtis
    Vanderkooi, Otto G.
    Li, Yan
    Halperin, Scott A.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (01) : 136 - 143
  • [20] Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months
    Carmona, Alfonso
    Omenaca, Felix
    Tejedor, Juan C.
    Merino, Jose M.
    Vaman, Tejaswini
    Dieussaert, Ilse
    Gillard, Paul
    Aristegui, Javier
    VACCINE, 2010, 28 (36) : 5837 - 5844